Telomerase and systems controlling their activity have been of great attention. There are controversies regarding the role of the alternative splicing forms of the human telomerase reverse transcriptase (hTERT), the catalytic subunit of telomerase. Therefore, the correlation between telomerase enzyme activity, the abundance of alternatively spliced variants of hTERT and doubling time of a series of cancer cell lines originated from hematopoietic, breast, colorectal, neural, ovarian, lung, kidney, bladder, prostate and head and neck cancers were investigated. Expression levels of four different variants of hTERT (the full length, α-deletion, β-deletion and α/β-deletion) were quantitatively measured by real time PCR. Telomerase activity was determined by the telomerase repeat amplification protocol (TRAP) while doubling time of the cells measured by plotting growth curves. Results showed high diversity in the relative proportions of hTERT transcripts while the majority of the cells expressed the full length variant as the main transcript. Telomerase activity could not be detected in all cells. Relative assessment of hTERT expression showed greater expression of the α-deleted variant in the telomerase negative cells (P= 0.04). Those cells possessed the α/β-deleted variant to a smaller extent when compared to the cells with telomerase activity. Greater association between full length spliced variant and β-variant expression was observed in cells presenting telomerase activity (P= 0.0007, r= 0.74). High degrees of variation among the studied cells regarding the pattern of hTERT expression were present. In spite that, the regulatory roles of hTERT on telomerase activity is still a potential to be utilized as targets for cancer therapies.
suggesting that transcription of the hTERT gene can act as a major regulatory step (6) . In fact, exogenous over expression of hTERT could immortalize a non neoplastic cell which supported the ideas that hTERT expression can act as a limiting factor for telomerase activity and as a target for cancer therapy as well (7) (8) . In addition to that, post transcriptional modifications of hTERT have been proposed to alter telomerase activity in cells (9) . hTERT transcript is known to have seven alternative splicing sites, from which multiple tissue specific and possibly disease specific alternative transcripts could be produced (10) . Therefore, the expression levels of hTERT variants could be the rate-limiting factor in telomerase activity (11) .
Several reports demonstrated the significant role of alternative splicing variants of hTERT as a factor regulating telomerase activity (12) , although controversies exist (9, 13). The most known variants of hTERT mRNA are alpha deletion variant (α-), beta deletion variant (β-) and
.
Experimental evidence showed that clones with β-deletion variant could not induce telomerase activity (15) . On the other hand, some other evidence showed that different alternatively spliced variants could promote cell proliferation and reduced apoptosis independent of the enzymatic activity of telomerase (16) (17) .
Therefore, in this study we correlated the 
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Statistical analyzes
The "one sample kolmogorov-Smirnov" test was used to determine the distribution of data. The
Spearman's correlation coefficient was used to find the relation between variables. P values less than 
Quantitative telomerase activity
TRAP assay was used to measure telomerase activity in the studied cell lines. Figure 4 demonstrates the corresponding quantities. As shown, significant telomerase activity could be All together, data show that cancer cells do not share a unique mechanism for the expression of the hTERT variants to regulate telomerase activity.
It has to be mentioned that the tested cells in this study were established cell lines which could affect the pattern of telomerase activity and hTERT expression. Despite the complexity of hTERT and telomerase machinery, they still have great potentials to be exploited as targets for cancer therapies. Therefore, more cells from same tissue origins or cancer tissues should be tested to draw a comprehensive conclusion.
